Who are Low dose hCG plus FSH co-trigger's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Ovarian Stimulation with CC+rFSH, r-FSH plus HP-hMG, FSH+LH, DUOSTIM.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/low-dose-hcg-plus-fsh-co-trigger.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Low dose hCG plus FSH co-trigger — Competitive Intelligence Brief

Low dose hCG plus FSH co-trigger (Low dose hCG plus FSH co-trigger) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Gonadotropin combination. Area: Reproductive Medicine / Fertility.

phase 3 Gonadotropin combination FSH receptor and hCG receptor (LH/hCG receptor) Reproductive Medicine / Fertility Small molecule Live · refreshed every 30 min

Target snapshot

Low dose hCG plus FSH co-trigger (Low dose hCG plus FSH co-trigger) — University of California, San Francisco. Low-dose hCG combined with FSH acts as a dual trigger to induce final oocyte maturation and ovulation in assisted reproductive technology cycles.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Low dose hCG plus FSH co-trigger TARGET	Low dose hCG plus FSH co-trigger	University of California, San Francisco	phase 3	Gonadotropin combination	FSH receptor and hCG receptor (LH/hCG receptor)
Ovarian Stimulation with CC+rFSH	Ovarian Stimulation with CC+rFSH	Fundación Santiago Dexeus Font	marketed	Gonadotropin combination therapy	FSH receptor (FSHR); estrogen receptor (ER) antagonism
r-FSH plus HP-hMG	r-FSH plus HP-hMG	Instituto Valenciano de Infertilidad, IVI VALENCIA	marketed	Gonadotropin combination	FSH receptor, LH receptor
FSH+LH	FSH+LH	Instituto Valenciano de Infertilidad, IVI VALENCIA	phase 3	Gonadotropin combination	FSH receptor (FSHR) and LH receptor (LHCGR)
DUOSTIM	DUOSTIM	Centre Hospitalier Intercommunal Creteil	phase 3	Gonadotropin combination therapy	FSH receptor and LH receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Gonadotropin combination class)

Instituto Valenciano de Infertilidad, IVI VALENCIA · 2 drugs in this class
University of California, San Francisco · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Low dose hCG plus FSH co-trigger — Competitive Intelligence Brief. https://druglandscape.com/ci/low-dose-hcg-plus-fsh-co-trigger. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab